39th week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090238824 | BREAST, GASTRIC AND PROSTATE CANCER ASSOCIATED ANTIGENS AND USES THEREFOR - Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens. | 2009-09-24 |
20090238825 | NOVEL RABBIT ANTIBODY HUMANIZATION METHODS AND HUMANIZED RABBIT ANTIBODIES - The present invention is directed to novel and improved methods for humanizing rabbit heavy and light variable regions. The resulting humanized rabbit heavy and light chains and antibodies and antibody fragments containing are well suited for use in immunotherapy and immunodiagnosis as they retain the antigen binding affinity of the parent antibody and based on their very high level of sequence identity to human antibody sequences should be essentially non-immunogenic in humans. The invention exemplifies the protocol for the manufacture of therapeutic humanized anti-human TNF-alpha and anti-human IL-6 antibodies. | 2009-09-24 |
20090238826 | INHIBITORS OF PLACENTAL GROWTH FACTOR FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMOR FORMATION AND/OR VASCULAR LEAKAGE - The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF | 2009-09-24 |
20090238827 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2009-09-24 |
20090238828 | Combinations for the Treatment of Diseases involving Cell Proliferation - Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) | 2009-09-24 |
20090238829 | Stabilized single domain antibodies - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 2009-09-24 |
20090238830 | PROTEIN - The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development. | 2009-09-24 |
20090238831 | MONOCLONAL ANTIBODIES AND USES THEREOF - The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders. | 2009-09-24 |
20090238832 | Novel compositions and method for the treatment of psoriasis - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis. | 2009-09-24 |
20090238833 | PROTEIN - The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer or lung cancer, for monitoring the effectiveness of colorectal cancer or lung cancer treatment, and for drug development. | 2009-09-24 |
20090238834 | IDENTIFICATION OF PROTEIN ASSOCIATED WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER - The present invention provides methods and compositions for screening, diagnosis and prognosis of HCC, glioblastoma and lung cancer, for monitoring the effectiveness of HCC, glioblastoma and lung cancer treatment, and for drug development. | 2009-09-24 |
20090238835 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2009-09-24 |
20090238836 | Hip kinase for fertility control - The present invention relates to the use of a pharmaceutical composition which comprises as active component at least one HipK4 nucleic acid, a HipK4 polypeptide, modulators of HipK4, antibodies directed against HipK4, a HipK4 antisense, and a HipK4 RNAi, for the diagnosis and treatment of fertility impairments and for contraception. The invention further relates to the use of this pharmaceutical composition for manufacturing a medicament for the treatment of fertility impairments. | 2009-09-24 |
20090238837 | High Affinity Siglec Ligands - The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cancer in a mammal that involves administering a Siglec ligand of the invention to the mammal, where the Siglec ligand is linked to a therapeutic agent. | 2009-09-24 |
20090238838 | INSULINOTROPIC PEPTIDE CONJUGATE USING AN IMMUNOGLOBULIN FC - The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs. | 2009-09-24 |
20090238839 | Somatic Transgene Immunization and Related Methods - The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell. | 2009-09-24 |
20090238840 | Therapeutic vaccine - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. | 2009-09-24 |
20090238841 | HIV VACCINE FORMULATIONS - Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject. | 2009-09-24 |
20090238842 | Vaccine for preventing and treating porcine progressive atrophic rhinitis - The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragments of recombinant subunit | 2009-09-24 |
20090238843 | RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS - The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA. | 2009-09-24 |
20090238844 | Porcine reproductive and respiratory syndrome virus strains and compositions - This invention relates to two attenuated strains of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic compositions comprising one or more strains of attenuated porcine reproductive and respiratory syndrome virus (PRRSV). | 2009-09-24 |
20090238845 | ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS - The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals. | 2009-09-24 |
20090238846 | S/O type external preparation - The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of the present invention comprises a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a hydrophilic medicine covered with a surfactant and is in a form of a solid. | 2009-09-24 |
20090238847 | Deodorant Particle - Disclosed is a deodorant particle having a BET specific surface area of 10 m | 2009-09-24 |
20090238848 | Use of an Extract of the Orchid Vanda Coerulea as a Skin Hydrating Agent - The present invention relates to the use, in a cosmetic composition, of an extract of at least one part of an orchid of the species | 2009-09-24 |
20090238849 | STRETCHABLE LAMINATED SHEET - A stretchable laminated sheet with hydrophilic properties, which particularly has an excellent feeling and stability in wearing and is capable of efficiently enhancing the effect and efficacy brought about by a liquid component on a skin or other object, when the stretchable laminated sheet is impregnated with the liquid component and wet and then used on the skin or other object. A stretchable laminated sheet, which is obtained by partially thermocompression-bonding and laminating a hydrophilic short fiber layer extensible in at least one direction and an microfiber layer having a elastomer long fiber of a fiber diameter of 15 μm or less at 50% or more by weight, wherein discontinuous and regular concave and convex parts caused by the partial thermocompression bonding are formed on a surface of the hydrophilic short fiber layer that is exposed on one surface of the stretchable laminated sheet, the total area of the concave parts is in a range of 3 to 40% of the area of the surface of the hydrophilic short fiber layer, and at least the elastomer long fiber of the microfiber layer is softened and consequently joined to a fiber constituting the hydrophilic short fiber layer in a sheet thickness direction of a section where the concave parts exist, whereby the hydrophilic short fiber layer and the microfiber layer are integrated with each other. | 2009-09-24 |
20090238850 | ANTIMICROBIAL MATERIALS - Materials, compositions, and medical devices for the treatment or prophylaxis of microbial, including bacterial, infections, comprising at least one water-insoluble ceramic compound and at least one metal species. Methods of making such materials, compositions and medical devices. | 2009-09-24 |
20090238851 | ANTIBACTERIAL ELECTRONIC DEVICE AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a method for manufacturing an antibacterial electronic device. The method includes the steps of: (1) dispersing antibacterial material into alcohol solution with a predetermined concentration to form an even mixture solution; (2) laying statically the even mixture solution for a predetermined period of time to obtain a uniform and steady antibacterial solution; (3) coating the antibacterial solution to a surface of an insulating shell of an electronic device, the surface of the insulating shell of the electronic device with the antibacterial solution being dried at a temperature ranging from 50-150 degrees centigrade for obtaining a continuous antibacterial layer tightly attached to the surface of the insulating shell. | 2009-09-24 |
20090238852 | METHODS FOR CONTROLLING INTRACELLULAR CALCIUM LEVELS ASSOCIATED WITH AN ISCHEMIC EVENT - Described herein are methods for controlling the intracellular calcium concentration in a subject prior to experiencing an ischemic event, while experiencing an ischemic event, or while suffering from ischemia. The methods comprise administering an effective amount of O-desulfated heparin to the subject. The methods described herein are also useful in treating the symptoms associated with ischemic events or ischemia. | 2009-09-24 |
20090238853 | Hybrid Biomedical Device Fabricated From Biomaterials and Coated With a Natural Extra Cellular Matrix (ECM) Coating - The present invention relates to a hybrid biomedical device formed from a prefabricated biomedical device and coated with an extracellular matrix coating which is produced by directly culturing mammalian cells on the prefabricated biomedical device. The purposes of applying such an ECM coating is to regulate the biological and cellular responses of a living tissue or a cellular environment that the hybrid biomedical device is intended to interact with. The ECM coating will provide necessary biological cues, biomechanical cues, structural cues, etc to regulate the biological and cellular responses of a living system. The invention further provides methods of making the hybrid biomedical device. | 2009-09-24 |
20090238854 | PLASTICIZERS FOR COATING COMPOSITIONS - A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof. | 2009-09-24 |
20090238855 | LAMINATE SHEET ARTICLES FOR TISSUE REGENERATION - The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue. | 2009-09-24 |
20090238856 | POLYSULFONE BLOCK COPOLYMERS AS DRUG-ELUTING COATING MATERIAL - A polymeric composition comprising a polysulfone polymer and an elastomeric polymer for use as a coating composition for coating an implantable device, such as a DES, and methods of making and using the implantable device are provided. | 2009-09-24 |
20090238857 | USE OF HYDROPHOBIC CROSSLINKING AGENTS TO PREPARE CROSSLINKED BIOMATERIAL COMPOSITIONS - The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bix(sulfosuccinimidyl) suberate, and dithiobis(succinimidylpropionate). Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications. | 2009-09-24 |
20090238858 | Compositions and Methods for Treating Ophthalmic Diseases - Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol com-pound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units with pendant carboxylic acid groups and poly(alkylene oxide) blocks relative to the weight percentage of the drug in the composition is effective to provide pseudo-zero order release of the drug from the composition during the sustained-release phase of drug delivery under physiological conditions. Ocular treatment methods and manufacturing methods are also disclosed. | 2009-09-24 |
20090238859 | SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS - The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers. | 2009-09-24 |
20090238860 | Adhesive Patch Less Irritative to Skin - Disclosed is an adhesive patch composed of an adhesive base agent and a supporting body wherein the adhesive base agent contains 3-30% by mass of a low-molecular-weight polyisobutylene and aluminum hydroxide and/or titanium oxide but not substantially containing water. Also disclosed is a skin irritation reducing agent used therefore. Further disclosed is an adhesive patch composed of a supporting body and an adhesive base agent which contains a thermoplastic rubber and a low-molecule-weight polyisobutylene but not substantially containing water. This adhesive patch is characterized in that the adhesive base agent further contains aluminum hydroxide and/or titanium oxide. Also disclosed is a skin irritation reducing agent used for such an adhesive patch. | 2009-09-24 |
20090238861 | FENTANYL SUSPENSION-BASED SILICONE ADHESIVE FORMULATIONS AND DEVICES FOR TRANSDERMAL DELIVERY OF FENTANYL - Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl. | 2009-09-24 |
20090238862 | Methods and Compositions for Seprase Inactivation - The present invention relates to isolated nucleic acids encoding short hairpin RNAs that interfere with seprase mRNA expression, vector and host cells for expressing seprase mRNA interfering short hairpin RNAs, and methods of therapeutic use of the same for preventing further tumor invasation and metastasis. | 2009-09-24 |
20090238863 | LIPOSOME COMPOSITION FOR INDUCTION OF IMMUNITY - It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen substance and is used to cause the MHC class I and class II molecules of an antigen-presenting cell to present an antigen peptide. | 2009-09-24 |
20090238864 | DNA VACCINES ENCODING HEAT SHOCK PROTEINS - The present invention is related to a method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 60 (HSP60), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences, and wherein the disease is other than insulin dependent diabetes mellitus (IDDM), thereby treating the disease. | 2009-09-24 |
20090238865 | LIPID NANOCAPSULES, PREPARATION PROCESS AND USE AS MEDICINE - The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine. | 2009-09-24 |
20090238866 | CHEWABLE CAPSULES - The invention provides an orally administrable chewable capsule comprising a capsule shell enclosing an oil-in-water emulsion in which the aqueous phase is gelled, or an oil droplet-containing dried residue of such an emulsion. | 2009-09-24 |
20090238867 | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same - Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections. | 2009-09-24 |
20090238868 | ABUSE-RESISTANT ORAL DOSAGE FORMS AND METHOD OF USE THEREOF - An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist. | 2009-09-24 |
20090238869 | PROPRANOLOL FORMULATIONS - Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose. | 2009-09-24 |
20090238870 | Dividable galenical form allowing modified release of the active ingredient - Dividable galenical form for the modified release of active ingredient, wherein the non-subdivided galenical form and a portion of said form obtained by subdivision have identical dissolution profiles. Medicaments. | 2009-09-24 |
20090238871 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described. | 2009-09-24 |
20090238872 | Chlorine dioxide releasing composite article - A composite article that includes a ClO | 2009-09-24 |
20090238873 | EXTENDED RELEASE FORMULATION CONTAINING A WAX - Extended release pharmaceutical formulations are disclosed wherein the formulations contain an extended release portion and an immediate release portion, the extended release portion comprising an active pharmaceutical ingredient and a wax. Methods of making such extended release pharmaceutical formulations are also disclosed. | 2009-09-24 |
20090238874 | BIOMIMETIC COMPOSITION REINFORCED BY A POLYELECTROLYTIC COMPLEX OF HYALURONIC ACID AND CHITOSAN - The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed. | 2009-09-24 |
20090238875 | Chitosan or Hyaluronic Acid-Poly(Ethylene Oxide)-and Chitosan-Hyaluronic Acid-Poly(Ethylene Oxide)-Based Hydrogel and Manufacturing Method Therefor - Disclosed are a chitosan-chitosan-polyethylene oxide hydrogel formed via covalent bonding between chitosan derivatives crosslinked with an acrylate or methacrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof; a hyaluronic acid-hyaluronic acid-polyethylene oxide hydrogel formed via covalent bonding between hyaluronic acid derivatives crosslinked with an acrylate or methacrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof; and a chitosan-hyaluronic acid-polyethylene oxide hydrogel formed via covalent bonding between a chitosan derivative crosslinked with a (meth)acrylate functional group-containing substance as well as a hyaluronic acid derivative crosslinked with a (meth) acrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof. | 2009-09-24 |
20090238876 | BISPHOSPHONATES FOR TREATING ENDOMETRIOSIS - A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject. | 2009-09-24 |
20090238877 | Agent For Improving Fine Wrinkles - An agent for improving fine wrinkles contains an oil based preparation for external use for skins, the oil based preparation containing: (i) 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and (ii) 5% by mass to 50% by mass of particles, the oil based preparation having occlusion characteristics of at least 50%. A beauty culture method for improving fine wrinkles comprises applying the oil based preparation for external use for skins onto a skin. | 2009-09-24 |
20090238878 | Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening - The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening. | 2009-09-24 |
20090238879 | DELIVERY SCAFFOLDS AND RELATED METHODS OF USE - The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening). | 2009-09-24 |
20090238880 | PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME - Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides. | 2009-09-24 |
20090238881 | IONOPHORE ANTIBIOTIC FORMULATIONS - The invention relates to an ionophore antibiotic composition capable of diluting with water to a substantially stable dispersed form in all water than present, said composition comprising or including:—at least one ionophore antibiotic (preferably monensin) of a mean particle size of less than 20 microns,—and at least one dispersing agent. A method of preparing the ionophore antibiotic composition is also disclosed. | 2009-09-24 |
20090238882 | Carbon-substituted diketopiperazine delivery systems - Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided. | 2009-09-24 |
20090238883 | LIVER-SPECIFIC NANOCAPSULES AND METHODS OF USING - This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells. | 2009-09-24 |
20090238884 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE - The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also provided. | 2009-09-24 |
20090238885 | PROTEIN ENCAPSULATED PARTICLES - Particles that are encapsulated by protein are provided. Also a method for preparing protein encapsulated particles involving spraying and drying of an activated protein solution is provided. The protein encapsulated particles are particularly suited for food, feed, cosmetic and pharma applications. | 2009-09-24 |
20090238886 | Retro-Inversion Peptides That Target GIT Transport Receptors and Related Methods - Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active site delivery across the GIT into the systemic circulation are provided. These retro-inverted peptides and compositions containing these retro-inverted peptides can be used to deliver an active agent, such as a drug or a drug-containing nano- or microparticle for treatment of a condition in a subject in need of the drug, in vivo. Additionally, the invention provides antibodies which are capable of immunospecifically binding the retro-inverted peptides. | 2009-09-24 |
20090238887 | Highly Impact-Resistant Granules - The present invention provides highly impact-resistant, water-soluble or water dispersible, low-dust granules comprising an active ingredient and methods for obtaining the same. | 2009-09-24 |
20090238888 | RADICAL POLYMERIZATION METHOD AND PRODUCTS PREPARED THEREBY - In one embodiment, the present invention relates to a method for initiating radical polymerization of at least one monomer composition, the method comprising the steps of: supplying at least one monomer charge; and initiating radical polymerization of the at least one monomer charge via a hydrogen peroxide initiator and at least one polyamine co-initiator, wherein the method is carried out in an inverse-microemulsion, the inverse-microemulsion being a water/oil emulsion. | 2009-09-24 |
20090238889 | Hyper-Branched Polymers for the Provision of Hygienic Characteristics - The invention relates to hyper-branched polymers having a hydrophobic core and an antimicrobial and/or anti-adhesive active shell for providing surfaces with semi-permanent hygienic characteristics. | 2009-09-24 |
20090238890 | CONTINUOUS SPRAY-CAPTURE PRODUCTION SYSTEM - The disclosure relates to novel microencapsulation processes based on the use of high viscosity fluids (e.g., gelatinized starch and alginate), which are mixed and then sprayed using a much gentler hydraulic pressure and, preferably gas-based atomization into a crosslinking solution (e.g. of calcium chloride). To improve the efficiency of the system, the process can be performed in a continuous mode rather than by a conventional batch process. This involves continuous or intermittent harvest of the microparticles collected in the capture vessel followed by amendment and recycling of the CaCl | 2009-09-24 |
20090238891 | Method of producing a dry earthworm powder - Provided is a method of producing a dry earthworm powder without deterioration in useful pharmacological action, by removing dirt on the skin of earthworms while allowing the earthworms to excrete the digest remaining in the digestive tracts efficiently without weakening the earthworms, which comprises the steps of: standing living earthworms under light for 10 to 50 hours, removing the dirt formed on the skin thereof, adding an organic acid to the living earthworms, diluting the acid rapidly with addition of water, adjusting the pH of the aqueous acidic solution to 2 to 5, standing the earthworm mixture for 3 to 180 minutes under the pH condition, washing the earthworms with water, grinding the earthworms into a homogenate, freezing the homogenate at −18° C to −35°0 C, keeping the frozen homogenate for 20 to 240 hours, and freeze-drying and degassing the frozen homogenate under vacuum simultaneously. | 2009-09-24 |
20090238892 | DEER ANTLER EXTRACT FOR PROMOTING ANGIOGENESIS - An isolated extract of deer velvet which contains components which have molecular weights that are substantially are less than or equal to 10 kDa and which have a proliferative effect on endothelial cells and/or promote angiogenesis. | 2009-09-24 |
20090238893 | NUTRITIONAL FORMULATION - A nutritional formulation for the treatment of inflammatory conditions of the gastrointestinal tract (particularly Crohn's Disease in paediatric patients) comprises: (a) a lipid source, (b) a carbohydrate source, and (c) a protein source. wherein the lipid source comprises a weight ratio of n-6:n-3 fatty acids of 1:1 to 3:1, at least 90% by weight of the n-3 fatty acids in the lipid source are provided by α-linolenic acid and at least 90% by weight of the n-6 fatty acids in the lipid source are provided by linoleic acid and components (a), (b) and (c) together provide at least 400 kcal of energy per 100 g total weight of (a)-(c). | 2009-09-24 |
20090238894 | THRUSH AND WHITE LINE MEDICINAL DELIVERY SYSTEM - An equine medicinal delivery system includes a dental roll impregnated with a medicinal solution for placement in an equine hoof. Another embodiment of an equine medicinal delivery system includes a pledget impregnated with a medicinal solution for placement in an equine hoof. A method of manufacturing an equine medicinal delivery system includes providing copper sulfate powder, combining water with the copper sulfate power to form a solution, and impregnating an applicator device with the solution. A method of manufacturing an equine medicinal delivery system includes providing an applicator device impregnated with a medicinal solution for placement in an equine hoof. | 2009-09-24 |
20090238895 | NUTRITIONAL AND/OR PHARMACEUTICAL PREPARATION FOR USE IN PROPHYLAXIS AND TREATMENT OF DISTURBANCES IN MICROELEMENTS ABSORPTION FROM THE ALIMENTARY CANAL - The invention dissolves the problem of the pharmaceutical preparation being a factor stimulating the absorption of microelements. The essence of the invention is that the preparation contains alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate, dipeptide of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and glutamate with other amino acid or/and salts of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate, dipepetides of glutamine or glutamate with other amino acid in a dose 0.01-0.5 g/kg/day and administered orally stimulates the absorption of iron, zinc, copper, manganese, strontium, calcium, phosphorus and other microelements from the alimentary canal to the blood ensuring proper—physiological—curative level of these compounds in the blood of people and animals. | 2009-09-24 |
20090238896 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MELANOMA - Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2009-09-24 |
20090238897 | REMOVAL OF SKIN CHANGES - The present invention relates to the field of skin disorders, particularly to the prevention and/or treatment of benignant or malignant changes of the epidermis visible in form of e.g. nevus. A pharmaceutical, dermatological and/or cosmetic composition is disclosed comprising as active constituent the boroxine compound. The present invention further provides the respective uses of the boroxine compound in medicine, particularly in the field of skin disorders, and in dermatological and/or cosmetic applications. | 2009-09-24 |
20090238898 | METHOD OF INHIBITING THE PROLIFERATION AND MIGRATION OF HELICOBACTOR PYLORI - strains are indigenous to each human host and infect and colonize in the stomach of the host, and they are also known to be involved in diseases of the upper gastrointestinal tracts, among others. The present invention provides an economical method for inhibiting the proliferation and migration of | 2009-09-24 |
20090238899 | METHOD FOR RAPID IDENTIFICATION OF PHARMACOLOGICALLY ACTIVE CHEMICAL ENTITIES ASSOCIATED WITH THE EFFICACY OF ETHNOBOTANICAL SUBSTANCES - The method includes the steps of performing in-vitro liver, intestinal and/or expressed enzyme assays with selected ethnobotanical substances, for both humans and a variety of animal species, to produce an array of resulting chemical entities, such as metabolites, for the human and the animals. Comparisons are then made between the chemical entities from the human in-vitro studies and the animal in-vitro studies to determine the closest match. The animal with the closest match is then used for an in-vivo study. If a match is present between the animal in-vivo results and the human in-vitro results, the matched chemical entity is isolated or synthesized and then further tested to determine the suitability of the matched chemical entity as a treatment drug. | 2009-09-24 |
20090238900 | NOVEL ANTI-DIABETIC HERBAL COMPOSITION, METHOD FOR PREPARING THE SAME AND USE THEREOF - Disclosed is an herbal composition for the treatment of Type II diabetes and their associated secondary complications in humans, wherein said composition comprising extract of roots of | 2009-09-24 |
20090238901 | Method for Treatment of Constipation-Predominant Irritable Bowel Syndrome - The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a | 2009-09-24 |
20090238902 | CHINESE MEDICINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF - This invention relates a traditional Chinese medicine composition and the drug containing this composition as well as preparation method and use thereof. The composition comprises 1-10 parts by weight of radix ginseng, 1-10 parts by weight of folium ginkgo, 0.05-0.5 parts by weight of stigma croci and 5-10 parts by weight of | 2009-09-24 |
20090238903 | PROCESS FOR THE PREPARATION OF SOUR CHERRY SEED EXTRACT, USE OF THE EXTRACT FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID EXTRACT - The present invention relates to a process for the isolation of the components of seed of | 2009-09-24 |
20090238904 | Compositions and Methods for Promoting Weight Loss - Compositions, which include psyllium and polyethylene glycol in a weight ratio of psyllium to polyethylene glycol of from about 1:3 to about 2:1, a gum, and one or more additional ingredients selected from the group consisting of water, salt, sweeteners, flavoring agents, and preservatives are presented. | 2009-09-24 |
20090238905 | INFLAMMATION REDUCING ACTION OF SYNERGISTIC MIXTURES OF BISABOLOL AND GINGER EXTRACTS - A formulation for treating or eliminating irritation and/or inflammation-reducing effect on endodermal tissue of the respiratory tract, the gastrointestinal tract, or both is disclosed. The formulation can include bisabolol or an extract containing bisabolol and actives found in ginger or extracted from ginger. The ratio of bisabolol and actives from ginger is adjusted such that the irritation and inflammation-reducing action of the bisabolol constituents and ginger constituents is increased synergistically. | 2009-09-24 |
20090238906 | FLAVOR IMPROVING AGENT - A taste improving agent containing as an active ingredient a whey mineral satisfying all the criteria (a), (b), (c), (d), and (e) below:
| 2009-09-24 |
20090238907 | Topical Compositions Containing Bacillus Coagulans Extracellular Products and Uses Thereof - The present invention discloses compositions derived from an isolated | 2009-09-24 |
20090238908 | ARRANGEMENT AND METHOD IN CONNECTION WITH EXTRUSION TOOLS - The invention relates to an arrangement in connection with extrusion tools. It comprises a nozzle structure which is provided with coaxially arranged nozzle elements ( | 2009-09-24 |
20090238909 | PLASTICS INJECTION MOLDING MACHINE WITH INJECTION FORCE MEASURING DEVICE - A plastics injection molding machine with an injection unit has an injection unit housing as central part of the injection unit, a plasticizing cylinder connected to the injection unit housing, a screw which is supported in the plasticizing cylinder for rotation to prepare injection material and for displacement to effect the injection stroke in axial direction, drive motors coupled to and generating the rotation and axial movements of the screw and supported on the injection unit housing via a motor flange, and an injection force measuring device for determining the injection force applied by the screw when executing its injection stroke, wherein the injection force measuring device includes at least one tensile force sensor which is integrated in the injection unit housing in such a manner that the reaction force of the injection force, as generated by the injection force and introduced via the motors and the motor flange into the injection unit housing, is detectable. | 2009-09-24 |
20090238910 | Apparatus for blow molding - A blow molding apparatus wherein an extruded tubular parison is pressurized to form a molded article, comprises a blow pin for introducing pressurized fluid into the parison, an actuator for advancing and retracting the blow pin and adjusting means for determining the orientation of the actuator to achieve substantial parallelism of a blow pin shaft to which the blow pin is attached and a centerline of the opening through a forming die through which the blow pin shaft passes and to achieve substantial parallelism of a sealing element of the blow pin with a plane transverse to the opening of the parison. | 2009-09-24 |
20090238911 | CLAY EXTRUDER - The clay extruder includes a drum | 2009-09-24 |
20090238912 | METHOD FOR USE IN BAKING ARTICLES OF MANUFACTURE AND MOLD FOR USE IN SAID METHOD - The present invention relates to a method for producing baked goods and a mold apparatus having a cavity in a desired shape for use in said method, the mold apparatus comprising a gap that allows for venting of vapor produced during heating or baking of a mixture in the mold apparatus but does not allow any significant amount of the mixture to escape from the cavity of the mold apparatus via the gaps. | 2009-09-24 |
20090238913 | MOLDING APPARATUS - A molding apparatus includes a first mold half, a first mold core received in the first mold half, a second mold half opposite to the first mold half, a second mold core and a plurality of spacers. The second mold core includes a sleeve and a core insert. The sleeve is received in the second mold core. The sleeve includes a receiving hole defined therein, and a plurality of parallel grooves defined in an inner surface in the receiving hole. The grooves are angularly equidistantly spaced from each other. The core insert is received in the receiving hole of the sleeve. The plurality of spacers is configured for being selectively disposed in the corresponding grooves. Each of the spacers is configured for being sandwiched between the sleeve and the core insert. | 2009-09-24 |
20090238914 | FEED MECHANISM OF MOLD - A feed mechanism of mold includes a top plate, an injection body and two slides. The top plate defines a recess in the bottom for receiving the two slides. The injection body is disposed in the top of the top plate and defines a sprue at the top thereof, a first pouring runner and a second runner both connecting with the sprue. The bottom of the first pouring runner penetrates through the injection body. The slide has a mating surface. The two mating surfaces of the two slides match each other. A shaping recess is defined between the mating surfaces for receiving a core insert. An injection runner is defined between the mating surfaces and connects with the first pouring runner to define a first runner. Two molding cavities are defined among the slides, the core insert and the injection body and connect with the first runner and the second runner respectively. | 2009-09-24 |
20090238915 | SENIOR FELINE FOOD - A feline pet food comprising a dietary level of protein and a supplemental amount of at least one amino acid in an amount sufficient to provide a feline lean body mass protection equivalent to about a 50% protein feline pet food. | 2009-09-24 |
20090238916 | USE OF SILICON OXIDE COMPOUNDS AS FREE-FLOW AGENTS IN THE PRODUCTION OF SOLID POLYVINYL ACETATE RESINS - Polyvinyl acetate polymers produced by mass polymerization or suspension polymerization are stabilized against blocking by addition of minor amounts of a silicon oxide compound during the pelletization process of mass polymerized polymers and prior to or during fluidized bed drying in the case of suspension polymerized polymers. The free flowing polymers are suitable for use as chewing gum bases, and for other uses. | 2009-09-24 |
20090238917 | FOOD INGREDIENTS AND FOOD PRODUCTS TREATED WITH AN OXIDOREDUCTASE AND METHODS FOR PREPARING SUCH FOOD INGREDIENTS AND FOOD PRODUCTS - A method of making an aldobionate product is described. The method may include providing a milk product having one or more reducing sugars, and maintaining a pH of the milk product at about 5.5 or more by adding a buffer compound to the milk product. The method may also include adding an oxidoreductase enzyme to the milk product, where at least a portion of the reducing sugar is oxidized into the aldobionate product. In addition, a method of making an aldobionate product is described that includes the steps of providing a milk product comprising a reducing sugar, mixing oxygen into the milk product, and adding an oxidoreductase enzyme to the milk product, where at least a portion of the reducing sugar is oxidized into the aldobionate product. | 2009-09-24 |
20090238918 | Corn Wet Milling Process - A corn wet-milling process comprises steeping corn kernels in an aqueous liquid, which produces softened corn; milling the softened corn in a first mill, which produces a first milled corn; separating germ from the first milled corn, thereby producing a germ-depleted first milled corn; milling the germ-depleted first milled corn in a second mill, producing a second milled corn; separating the second milled corn into a first starch/protein portion that comprises starch and protein and a first fiber portion that comprises fiber, starch, and protein; milling the first fiber portion in a third mill, which produces a milled fiber material that comprises fiber, starch, and protein; separating at least some of the starch and protein in the milled fiber material from the fiber therein, producing a second fiber portion that comprises fiber and starch and a second starch/protein portion that comprises starch and protein; and contacting the second fiber portion with at least one enzyme to convert at least some of the starch therein to dextrose. The converted material is screened using one or more screens to separate the fiber from the liquor. The liquor can be fermented to ethanol, or refined to dextrose. The fiber can be pressed and dried as an animal feed. | 2009-09-24 |
20090238919 | METHOD OF MANUFACTURING VINEGAR WITH HIGH EXTRACT CONTENT - The object of the present invention is to provide a method of manufacturing vinegar with high extract content that keeps the original flavor of raw materials and has favorable flavor for vinegar under the circumstance of high extract content. | 2009-09-24 |
20090238920 | Process for making high grade protein product - A process for making a high grade protein product, such as a mammalian feed product, using residue slurry from a cellulose fermentation and distillation process is provided. The residue slurry is compressed to remove much of the residual liquid. The compressed slurry is shaped, dried, leavened and granulated to provide the high grade protein product. Nutrients, flavorants, texturizers and other food product-enhancing ingredients may be added during the process. The granules of animal feed product can be packaged and stored in an inert or other stable environment for extended storage periods. | 2009-09-24 |
20090238921 | MUTANT STRAINS OF LACTIC ACID BACTERIA HAVING A NON-PHOSPHORYLABLE LACTOSE PERMEASE - The invention concerns lactic acid bacteria strains wherein the phosphorylable histidine of the IIA domain of lactose permease is replaced by a non-phosphorylable amino acid. Said strains have a reduced post-acidification and are useful in particular for preparing fermented dairy products. | 2009-09-24 |
20090238922 | PROTEASES - The invention relates to a novel class of serine proteases of peptidase family S2A or S1E that are stable in the presence of copper (Cu | 2009-09-24 |
20090238923 | VARIANTS OF BACILLUS LICHENIFORMIS ALPHA-AMYLASE WITH INCREASED THERMOSTABILITY AND/OR DECREASED CALCIUM DEPENDENCE - Variants of | 2009-09-24 |